Otake K, Misu S, Yamamoto A, Yamaguchi T, Nagatani C, Sakai H
Respir Care. 2025; 70(1):56-64.
PMID: 39964866
PMC: 11824878.
DOI: 10.1089/respcare.11712.
Tan Z, Lou Y, Qin Y, Lin W, Liang B, Sooranna S
Int J Med Sci. 2024; 21(6):1079-1090.
PMID: 38774751
PMC: 11103402.
DOI: 10.7150/ijms.93510.
Deng J, Liu J, Chen W, Liang Q, He Y, Sun G
Drug Des Devel Ther. 2024; 18:1627-1650.
PMID: 38774483
PMC: 11108075.
DOI: 10.2147/DDDT.S388920.
Singh S, Wairkar S
AAPS PharmSciTech. 2024; 25(4):78.
PMID: 38589751
DOI: 10.1208/s12249-024-02793-y.
Yao L, Xu Z, Davies D, Jones M, Wang Y
Chin Med J Pulm Crit Care Med. 2024; 2(1):27-33.
PMID: 38558961
PMC: 7615773.
DOI: 10.1016/j.pccm.2024.02.001.
The role of lung biopsy for diagnosis and prognosis of interstitial lung disease in systemic sclerosis: a systematic literature review.
Damiani A, Orlandi M, Bruni C, Bandini G, Lepri G, Scaletti C
Respir Res. 2024; 25(1):138.
PMID: 38521926
PMC: 10960984.
DOI: 10.1186/s12931-024-02725-1.
Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan.
Liao K, Chen C
Front Pharmacol. 2024; 15:1309712.
PMID: 38384288
PMC: 10879927.
DOI: 10.3389/fphar.2024.1309712.
The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases.
Luppi F, Manfredi A, Faverio P, Brun Andersen M, Bono F, Pagni F
BMC Pulm Med. 2023; 23(1):501.
PMID: 38082233
PMC: 10714466.
DOI: 10.1186/s12890-023-02783-z.
Mass spectrometry-based autoimmune profiling reveals predictive autoantigens in idiopathic pulmonary fibrosis.
Leuschner G, Semenova A, Mayr C, Kapellos T, Ansari M, Seeliger B
iScience. 2023; 26(11):108345.
PMID: 38026226
PMC: 10661358.
DOI: 10.1016/j.isci.2023.108345.
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan.
Iwasaki K, Wakabayashi H, Saiki A, Ueshiba H, Murakami Y, Matsuzawa Y
Drugs Real World Outcomes. 2023; 11(1):43-52.
PMID: 37883007
PMC: 10928060.
DOI: 10.1007/s40801-023-00396-w.
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis.
Oldham J, Huang Y, Bose S, Ma S, Kim J, Schwab A
Am J Respir Crit Care Med. 2023; 209(9):1111-1120.
PMID: 37847691
PMC: 11092951.
DOI: 10.1164/rccm.202301-0117OC.
SIgA in various pulmonary diseases.
Wang X, Zhang J, Wu Y, Xu Y, Zheng J
Eur J Med Res. 2023; 28(1):299.
PMID: 37635240
PMC: 10464380.
DOI: 10.1186/s40001-023-01282-5.
Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective.
Mai T, Han L, Hsu J, Kamath N, Pan L
Ther Adv Respir Dis. 2023; 17:17534666231181537.
PMID: 37392011
PMC: 10333628.
DOI: 10.1177/17534666231181537.
Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis.
Li J, Chang W, Li L, Yang D, Hsu S, Kenyon N
Respir Res. 2023; 24(1):132.
PMID: 37194070
PMC: 10189934.
DOI: 10.1186/s12931-023-02421-6.
Cloning a profibrotic stem cell variant in idiopathic pulmonary fibrosis.
Wang S, Rao W, Hoffman A, Lin J, Li J, Lin T
Sci Transl Med. 2023; 15(693):eabp9528.
PMID: 37099633
PMC: 10794039.
DOI: 10.1126/scitranslmed.abp9528.
Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs.
Guilherme R, Silva J, Waclawiack I, Fraga-Junior V, Nogueira T, Pecli C
Front Immunol. 2023; 14:886601.
PMID: 36960058
PMC: 10030054.
DOI: 10.3389/fimmu.2023.886601.
NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan.
Cheng S, Sheu C, Chian C, Hsu J, Kao K, Hang L
Biomedicines. 2022; 10(10).
PMID: 36289624
PMC: 9598748.
DOI: 10.3390/biomedicines10102362.
Mechanoresponsive regulation of fibroblast-to-myofibroblast transition in three-dimensional tissue analogues: mechanical strain amplitude dependency of fibrosis.
Jacho D, Rabino A, Garcia-Mata R, Yildirim-Ayan E
Sci Rep. 2022; 12(1):16832.
PMID: 36207437
PMC: 9547073.
DOI: 10.1038/s41598-022-20383-5.
Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.
Han M, Song Y, Liu S, Lu X, Su L, Liu M
Front Pharmacol. 2022; 13:882678.
PMID: 35548360
PMC: 9081653.
DOI: 10.3389/fphar.2022.882678.
A Retrospective, Descriptive Study of Dyspnea Management in a Multidisciplinary Interstitial Lung Disease Clinic.
Van den Bosch L, Wang T, Bakal J, Richman-Eisenstat J, Kalluri M
Am J Hosp Palliat Care. 2022; 40(2):153-163.
PMID: 35484838
PMC: 9850391.
DOI: 10.1177/10499091221096416.